PS
REGN icon

Planned Solutions’s Regeneron Pharmaceuticals REGN Stock Holding History

Planned Solutions’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-241
Closed -$253K – 511
2024
Q3 		$253K Buy
241
+7
+3% +$7.79K 0.1% 95
2024
Q2 		$246K Hold
234
– – 0.12% 77
2024
Q1 		$225K Hold
234
– – 0.11% 85
2023
Q4 		$206K Buy
+234
New +$193K 0.1% 82

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Planned Solutions's REGN Position: Q4 2024 in Review

Planned Solutions sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 241 shares — an estimated $253K sold.

Planned Solutions first reported a position in REGN in Q4 2023 and held it in 4 quarters. The position peaked at $253K in Q3 2024. 1,317 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

  • Planned Solutions reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Planned Solutions sold 241 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $253K.
  • Planned Solutions first reported a position in Regeneron Pharmaceuticals in Q4 2023 and held it in 4 quarters.
  • Planned Solutions's Regeneron Pharmaceuticals position peaked at $253K in Q3 2024.
  • 1,317 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on Planned Solutions's 13F filing for Q4 2024, filed 17 Jan 2025.